Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05404750 · ClinicalTrials.gov registry record
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
A clinical trial of Substance Use and Human Immunodeficiency Virus, sponsored by University of Pittsburgh.
- Recruiting
- Registry status
- 768
- Enrollment target
- 3
- Study locations
NCT05404750: Recruiting study of Substance Use and Human Immunodeficiency Virus, sponsored by University of Pittsburgh.
NCT05404750 is a study of Substance Use and Human Immunodeficiency Virus that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 768 participants, below the 1,252-participant average among 88 other Substance Use trials with a reported enrollment target (39% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05404750, a study of Substance Use and Human Immunodeficiency Virus, is actively recruiting participants, sponsored by University of Pittsburgh.
- RECRUITING
- Registry status
- 768 participants
- Enrollment target
- 3
- Study locations
Study Summary
People living with HIV (PLWH) who use drugs experience significant health disparities including lower rates of retention in HIV care and higher rates of unsuppressed viral load, resulting in secondary infections and increased mortality. The proposed study will used mixed methods to explore (a) the relationship between healthcare providers' attitudes towards working with PLWH who use drugs and providers' acceptance and practice of structural and relational harm reduction; (b) the degree to which relational harm reduction moderates the effect of intersectional stigma experienced in healthcare settings on patients' perceptions of their relationship with providers; (c) the degree to which structural HR moderates the relationship between the patient-provider relationship and clinical outcomes, and (d) whether patient-perceived HR approaches to care are directly associated with HIV clinical outcomes. The study will also use these findings to inform the development and pre-testing of an intervention to operationalize harm reduction in HIV clinical settings, using stakeholder-engaged and human-centered design approaches, presenting a novel path to reducing HIV health inequities for PLWH who use drugs.
Primary Outcome
Viral load will be assessed as a continuous and dichotomous variable (virally suppressed \<200 copies/ml)
Conditions Studied
Interventions
- BEHAVIORAL Harm Reduction
Study Locations (3)
Pennsylvania
- Allegheny Health Network Research Institute - Pittsburgh
- University of Pittsburgh Medical Center - Pittsburgh
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 768 participants |
| Start Date | 2022-04-20 |
| Est. Completion | 2026-06-30 |
What NCT05404750 shows while recruiting
NCT05404750 is an observational study that tracks outcomes without assigning an intervention. The registered 768 participants enrollment target is mid-sized for trials with a published cap, below the 1,252-participant average among 88 other Substance Use trials with a reported enrollment target (39% lower).
The record links to 3 conditions, with Substance Use appearing as the primary indexed condition, and to 1 intervention - of which Harm Reduction is the first listed.
NCT05404750 reports a single indexed study location in Pennsylvania, Alabama.
Frequently Asked Questions
What is clinical trial NCT05404750 about?
NCT05404750 is a clinical study titled "Harm Reduction in HIV Primary Care for PLWH Who Use Drugs". People living with HIV (PLWH) who use drugs experience significant health disparities including lower rates of retention in HIV care and higher rates of unsuppressed viral load, resulting in secondary infections and increased mortality. The proposed study will used mixed methods to explore (a) the r...
What is the current status of trial NCT05404750?
This trial is currently recruiting. The enrollment target is 768 participants. The study started on 2022-04-20. Estimated completion is 2026-06-30.
What conditions does trial NCT05404750 study?
This clinical trial studies the following conditions: Substance Use, Human Immunodeficiency Virus, Stigma, Social.
What interventions are being tested in trial NCT05404750?
The interventions under investigation include: Harm Reduction (BEHAVIORAL).
Who is sponsoring clinical trial NCT05404750?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05404750 being conducted?
This trial has 3 study locations across Alabama, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05404750's enrollment target sits among peer trials
768 11th of 88 higher than 78 of 88 other Substance Use trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Native Spirit: Significant Aim 3: Intervention
RECRUITING · NA
-
Parent SMART (Substance Misuse in Adolescents in Residential Treatment)
RECRUITING · NA
-
Cultural Adaptation of Drug Treatment for DJJ Youth
RECRUITING · NA
-
Adaptation and Evaluation of Bright Horizons
RECRUITING · NA
-
Teen Health Choices & Wellness
RECRUITING · NA
-
Pre-exposure Prophylaxis (PrEP) Uptake and Adherence Intervention for Women with Trauma-related Conditions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05119556 · 768 participants · NA
Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease
- NCT05660525 · 768 participants · NA
Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia
- NCT06324357 · 768 participants · Phase 1
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- NCT07076485 · 768 participants · Phase 2
Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI